Navigation Links
Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/2/2013

LAVAL, Quebec, May 2, 2013 /PRNewswire/ --

  •  2013 First Quarter Total Revenue $1.068 billion; an increase of 25% over the prior year
  •  2013 First Quarter Product Sales $1.039 billion; an increase of 38% over the prior year
  •  Organic growth (same store sales) was 6%, excluding the impact from generics, primarily BenzaClin and Cesamet
  •  Pro forma organic growth was 4%, excluding the impact from generics, primarily BenzaClin and Cesamet
  •  2013 First Quarter GAAP EPS Loss of $0.09; Cash EPS $1.30, an increase of 43% over the prior year, excluding one-time items in 2012 first quarter
  •  2013 First Quarter GAAP Operating Cash Flow $255 million; Adjusted Operating Cash Flow $345 million; an increase of 35% over the prior year, excluding one-time items in 2012 first quarter
  •  2013 Guidance for Cash EPS raised to $5.55 to $5.85 despite entry of Zovirax generic ointment
  • Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announces first quarter financial results for 2013.

    "Despite a slow January due to the integration of the Valeant and Medicis sales organizations, we delivered another solid quarter of strong growth in Cash EPS and adjusted cash flow to our shareholders," stated J. Michael Pearson, chairman and chief executive officer.  "We were particularly pleased with the strong organic growth of our emerging market segment, which was primarily driven by Poland, Russia, Brazil, South East Asia, and South Africa, as well as the continued growth in many of our promoted brands."

    RevenueValeant's total revenues were $1.068 billion, up 25% compared to the first quarter of 2012, and product revenues were $1.039 billion, up 38% versus the year-ago quarter. 

    Valeant's U.S. Promoted product sales increased 91% to $479 million led by strong growth in key brands such as Acanya, CeraVe, Arestin, Dysport, Restylane, Perlane and AcneFree.  On a same store sales organic growth basis, U.S. Promoted business increased 6% despite increased generic competition in BenzaClin. Excluding the impact on BenzaClin sales, same store sales organic growth for this portfolio would have been 12% for the first quarter of 2013.  Pro forma organic growth was flat as compared to the prior year due to the harmonization of wholesaler contracts between Valeant and Medicis.  The wholesaler inventory levels of the Medicis dermatology portfolio were reduced from more than two months to approximately one month.  Excluding this impact, pro forma organic growth was 7% in the first quarter of 2013.

    Our U.S. Neurology and Other business delivered an EBITA contribution that was flat as compared to the prior year based on the stabilization of Wellbutrin XL and growth in several orphan drug products.  This improvement was achieved in spite of a decrease in overall sales primarily from a reduction in partnered generic products which are low margin (e.g. diltiazem CD, nifedipine) and the slow launch of fenofibrate. We expect the top line growth in this division to be flat to slightly up for the full year 2013 and growth in EBITA versus 2012.

    Our Canadian business reported strong growth in key brands for the quarter, including COLD-FX, CeraVe and our dermatology franchise, which was offset by the continued decline in Cesamet, while our Australian operations continued to perform well.

    Finally, our Emerging Markets segment performed extremely well in the first quarter and product sales increased 26% driven by outstanding growth in Poland, Russia, Brazil, South East Asia and South Africa. 

    Financial PerformanceThe Company reported a net loss of $28 million for the first quarter of 2013, or a loss of $0.09 per diluted share.  On a Cash EPS basis, adjusted income was $405 million, or $1.30 per diluted share.  Excluding gains on the divestiture of two dermatology products and a foreign exchange gain related to the acquisition of iNova in the first quarter of 2012, Cash EPS increased 43% over the year-ago quarter.GAAP cash flow from operations was $255 million in the first quarter of 2013, and adjusted cash flow from operations was $345 million.

    The Company's cost of goods sold (COGS) was $285 million in the first quarter of 2013.  After backing out the fair value adjustment to inventory, amortization expense and other items related to acquisitions, COGS represented 22% of product sales, a decrease of three percentage points as compared to the first quarter of 2012 due to a favorable product mix, global plant consolidations and other initiatives.Selling, General and Administrative expenses were $242 million in the first quarter of 2013, or approximately 23% of revenue, which was an increase of 4% over the prior year.  SG&A was unusually high this quarter due to the integration of Medicis, and we expect this ratio to return to historical levels for the remainder of 2013. Research and Development expenses were $24 million in the first quarter of 2013, or approximately 2% of revenue.

    2013 GuidanceThe Company is updating its previous Cash EPS guidance and is now targeting Cash EPS of $5.55 to $5.85 in 2013, despite a recent entry of Zovirax generic ointment, up from prior guidance of $5.45 to $5.75. Total revenue in the range of $4.4 to $4.8 billion and adjusted cash flow from operations of $1.5 to $1.75 billion is reaffirmed.  

    Conference Call and Webcast InformationThe Company will host a conference call and a live Internet webcast along with a slide presentation today at 7:30 a.m. ET (4:30 a.m. PT), May 2, 2013 to discuss its first quarter financial results for 2013. The dial-in number to participate on this call is (877) 876-8393 confirmation code 41820189. International callers should dial (973) 200-3961, confirmation code 41820189. A replay will be available approximately two hours following the conclusion of the conference call through May 9, 2013 and can be accessed by dialing (855) 859-2056, or (404) 537-3406, confirmation code 41820189. The live webcast of the conference call may be accessed through the investor relations section of the Company's corporate website at www.valeant.com.

    About ValeantValeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

    Forward-looking StatementsThis press release may contain forward-looking statements, including, but not limited to, statements regarding our expected performance for 2013, including 2013 guidance with respect to Cash EPS, total revenue and adjusted cash flow from operations, and COGS for 2013.  Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target", or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof.  Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

    Non-GAAP Information  To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the company uses non-GAAP financial measures that exclude certain items, such as amortization of inventory step-up, amortization of alliance product assets & pp&e step up, stock-based compensation step-up, contingent consideration fair value adjustments, restructuring, acquisition-related and other costs, acquired in-process research and development ("IPR&D"), legal settlements outside the ordinary course of business, the impact of currency fluctuations, amortization and other non-cash charges, amortization of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest, loss on extinguishment of debt, (gain) loss on assets held for sale/impairment, net, (gain) loss on investments, net, and adjusts tax expense to cash taxes. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a meaningful, consistent comparison of the company's core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP.  Therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

    Financial Tables follow.Contact Information:
    Laurie W. Little
    949-461-6002
    laurie.little@valeant.com Valeant Pharmaceuticals International, Inc. Table 1 Condensed Consolidated Statements of Income (Loss)For the Three Months Ended March 31, 2013 and 2012Three Months EndedMarch 31,(In thousands, except per share data)20132012Product sales$  1,038,867$
    750,880Alliance and royalty9,25879,231Service and other20,23025,992Total revenues1,068,355856,103Cost of goods sold (exclusive of amortization of intangible assets shown separately below)284,904224,196Cost of services14,95118,820Cost of alliances47868,820Selling, general and administrative ("SG&A")241,899177,286Research and development23,79522,006Acquisition-related contingent consideration(2,185)9,839Legal settlements and related fees4,4483,155Restructuring, acquisition-related and other costs56,88469,842Amortization of intangible assets326,175200,643951,349794,607Operating Income (loss)117,00661,496Interest expense, net(153,719)(100,902)Loss on extinguishment of debt(21,379)(133)Gain (loss) on investments, net1,8592,059Foreign exchange and other1,43924,299Income (loss) before (recovery) provision for income taxes(54,794)(13,181)Recovery of income taxes (27,264)(260)Net (loss) income$
    (27,530)
    $
    (12,921)
    Earnings per share:Basic and Diluted:Net loss$
    (0.09)
    $
    (0.04)
    Shares used in per share computation305,763307,776 Valeant Pharmaceuticals International, Inc. Table 2 Reconciliation of GAAP EPS to Cash EPS For the Three Months Ended March 31, 2013 and 2012Three Months EndedMarch 31,(In thousands, except per share data)20132012Net (loss) income$
    (27,530)$
    (12,921)Non-GAAP adjustments(a):Inventory step-up (b)43,24133,031Alliance product assets & pp&e step-up/down(c)13850,721Stock-based compensation step-up (d)(280)10,428Acquisition-related contingent consideration(e)(2,185)9,839Legal settlements and related fees(f)4,4483,155Restructuring, acquisition-related and other costs(g)56,88469,842Amortization and other non-GAAP charges(h)336,775205,203439,021382,219Amortization of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest(i)9,6475,750Loss on extinguishment of debt21,379133Tax(j)(37,355)(14,859)Total adjustments432,692373,243Adjusted net income$
    405,162
    $
    360,322
    GAAP earnings per share - diluted$
    (0.09)
    $
    (0.04)
    Cash earnings per share - diluted$
    .30
    $
    .14
    Cash earnings per share excluding one-time items - diluted$
    .30
    $
    .91
    Shares used in diluted per share calculation - Cash earnings per share312,350316,397(a) See footnote (a) to Table 2a.(b) See footnote (b) to Table 2a.(c) See footnote (d) to Table 2a.(d) See footnote (e) to Table 2a.(e) See footnote (f) to Table 2a.(f) See footnote (g) to Table 2a.(g) See footnotes (h) (i) Table 2a.(h) See footnote (c) to Table 2a.(i) See footnote (j) to Table 2a.(j) See footnote (k) to Table 2a. Valeant Pharmaceuticals International, Inc. Table 2a Reconciliation of GAAP EPS to Cash EPS For the Three Months Ended March 31, 2013 and 2012Non-GAAP Adjustments(a)forThree Months EndedMarch 31,(In thousands, except per share data)20132012Product sales$
    -$
    -Alliance and royalty--Service and other--Total revenues--Cost of goods sold (exclusive of amortization of intangible assets shown separately below)(53,989)

     (b)(c) 

    (36,421)

     (b)(c) Cost of services--Cost of alliances-(50,958)

     (d) Selling, general and administrative ("SG&A")290

     (e) 

    (11,361)

     (e) Research and development--Acquisition-related contingent consideration2,185

     (f) 

    (9,839)

     (f) Legal settlements and related fees(4,448)

     (g) 

    (3,155)

     (g) Restructuring, acquisition-related and other costs(56,884)

     (h) 

    (69,842)

     (i) Amortization of intangible assets(326,175)(200,643)(439,021)(382,219)Operating Income (loss)439,021382,219Interest expense, net9,647

     (j) 

    5,750

     (j) Loss on extinguishment of debt21,379133Gain (loss) on investments, net--Foreign exchange and other--Income (loss) before (recovery) provision for income taxes470,047388,102(Recovery) provision for income taxes 37,355

     (k) 

    14,859

     (k) Total Adjustments to Net income $
    432,692
    $
    373,243
    Earnings per share:Diluted:Total Adjustments to Net income$
    .39
    $
    .18
    Shares used in per share computation312,350316,397(a) To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the company uses non-GAAP financial measures that exclude certain items, such as amortization of inventory step-up, amortization of alliance product assets & pp&e step up, stock-based compensation step-up, contingent consideration fair value adjustments, restructuring, acquisition-related and other costs, acquired in-process research and development ("IPR&D"), legal settlements outside the ordinary course of business, the impact of currency fluctuations, amortization and other non-cash charges, amortization of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest, loss on extinguishment of debt, (gain) loss on assets held for sale/impairment, net, (gain) loss on investments, net, and adjusts tax expense to cash taxes. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a meaningful, consistent comparison of the company's core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP.  Therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. (b) ASC 805, accounting for business combinations requires an inventory fair value step-up whose total impact for the three months ended March 31, 2013 is $43.2 million primarily relating to the acquisition of Medicis Pharmaceutical Corporation on December 11, 2012.  For the three months ended March 31, 2012 the impact of inventory fair value step-up is $33.0 million primarily relating to the acquisitions of Dermik on December 16, 2011 and iNova on December 21, 2011.(c) For the three months ended March 31, 2013 and 2012 cost of goods include costs associated with integration related tech transfers, $7.6 million and $1.6 million, respectively.  For the three months ended March 31, 2013 cost of goods includes a BMS fair value inventory adjustment of $2.1 million.(d) Cost of Alliances represents the divestiture of 5-FU and IDP-111 resulting from the acquisition of Dermik, $50.9 million for the three months ended March 31, 2012. (e)  For the three months ended March 31, 2013 and 2012 SG&A primarily includes an insignificant amount and $10.4 million of stock-based compensation, respectively, which reflects the amortization of the fair value step-up increment resulting from the merger of Legacy Valeant into Legacy Biovail and the acceleration of certain equity instruments.(f) Net expenses from the changes in acquisition related contingent consideration for the three months ended March 31, 2013 and 2012 of $2.2 million and $9.8 million, respectively.(g)  For the three months ended March 31, 2013 and 2012 legal settlement costs of $4.4 million and $3.2 million, respectively, relate to settlements and associated legal fees of patent-related litigations.(h) Restructuring, acquisition-related and other costs of $56.9 million primarily represents costs related to the acquisition of Medicis and other Valeant restructuring and integration initiatives.
    These include $24.5 million related to integration consulting, duplicative labor, transition services, and other, $15.8 million related to employee severance costs, $7.9 million related to acquisition costs, $4.3 million related to facility closure costs, $2.7 million related to other, and $1.7 million related to non-personnel manufacturing integration costs.(i) Restructuring, acquisition-related and other costs of $69.8 million represent costs related to the merger of Legacy Valeant into Legacy Biovail and the acquisitions of Afexa, iNova, Dermik, Sanitas, Ortho Dermatologics, PharmaSwiss SA, Probiotica and Eyetech.  These costs include $20.2 million related to facility closure costs, $20.5 million related to contract cancellation fees, consulting, legal and other costs, $19.8 million related to severance, $7.5 million related to acquisition costs, and $1.8 million related to manufacturing integration.(j) Non cash interest expense associated with amortization and write-down of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest totals for the three months ended March 31, 2013 and 2012 of $9.6 million and $5.8 million, respectively.(k) Total tax effect of non-GAAP pre-tax adjustments, resolution of uncertain tax positions and change in valuation allowance associated with deferred tax asset. Valeant Pharmaceuticals International, Inc. Table 3 Statement of Revenues - by SegmentFor the Three Months Ended March 31, 2013 and 2012(In thousands) Three Months Ended March 31,Revenues(a)(b)2013
    GAAP2012
    GAAP%
    Change2013 currency impact2013 excluding currency impact
     non-GAAP%
    ChangeU.S. Promoted

    $
    482,636$
    327,95547%$
    -$
    482,63647%U.S. Neurology & Other

    159,966158,3641%-159,9661%Canada/Australia

    128,542132,569-3%1,384129,926-2%Developed Markets771,144618,88825%1,384772,52825%Emerging Markets-Central/Eastern Europe

    186,166144,39829%(300)185,86629%Emerging Markets-Latin America

    81,70970,87415%3,16084,86920%Emerging Markets-Southeast Asia/Africa

    29,33621,94334%1,70631,04241%Emerging Markets297,211237,21525%4,566301,77727%Total Revenues$   1,068,355$
    856,103
    25%$
    5,950
    $  1,074,30525%(a) Note: Currency effect for constant currency sales is determined by comparing 2013 reported amounts adjusted to exclude currency impact, calculated using 2012 monthly average exchange rates, to the actual 2012 reported amounts. Constant currency sales is not a GAAP-defined measure of revenue growth. Constant currency sales as defined and presented by us may not be comparable to similar measures reported by other companies. (b) See footnote (a) to Table 2a. Valeant Pharmaceuticals International, Inc.Table 4Reconciliation of GAAP Cost of Goods Sold to Non-GAAP Cost of Goods Sold - by SegmentFor the Three Months Ended March 31, 2013(In thousands)4.1Cost of goods sold (a) Three Months Ended March 31,2013
    as reported
    GAAP%
    of product sales2013
     fair value step-up adjustment to inventory and Other non-GAAP
    (b)2013 excluding fair value step-up adjustment to inventory and Other
    non-GAAP%
    of product salesDeveloped Markets$  159,41221%$
    46,904$
    2,50815%Emerging Markets125,49244%7,085118,40741%$  284,90427%$
    53,989
    $
    230,915
    22%(a) See footnote (a) to Table 2a.(b) Developed Markets includes $41.0 million of fair value step-up adjustment to inventory and $6.1 million of integration related tech transfer costs offset by PP&E step down of $0.2 million.  Emerging Markets includes $2.2 million of fair value step up adjustment to inventory, $1.5M of integration related tech transfer costs, $2.1 million BMS fair value inventory adjustment and $1.3 million of PP&E step up and other. Valeant Pharmaceuticals International, Inc.Table 5Consolidated Balance Sheet and Other Data(In thousands)As ofAs ofMarch 31,December 31,5.1Cash20132012Cash and cash equivalents

    $
    413,736$
    916,091Marketable securities

    10,0924,410Total cash and marketable securities

    $
    423,828
    $
    920,501
    DebtNew Term Loan A Facility

    $   1,926,577$   2,083,462New Term Loan B Facility

    1,265,7261,275,167New Incremental Term Loan B Facility

    973,765973,988Senior Notes

    6,450,0016,448,317Convertible Notes

    209233,793Other

    84289810,617,12011,015,625Less: Current portion

    (289,676)(480,182)$ 10,327,444$ 10,535,4435.2Summary of Cash Flow StatementThree Months EndedMarch 31,20132012Cash flow provided by (used in):Net cash provided by operating activities (GAAP)

    $
    255,349167,230Restructuring, acquisition-related and other costs (c)

    56,88469,842Payment of accrued legal settlements

    2,82060Payment of accreted interest on convertible debt

    -56Tax Benefit from stock options exercised (a)

    4,604593Working Capital change related to business development activities

    19,981-Changes in working capital related to restructuring, acquisition-related and other costs(c)

    5,75017,539Adjusted cash flow from operations (Non-GAAP) (b)

    $
    345,388$
    255,320(a) Includes stock option tax benefit which will reduce taxes in future periods.(b) See footnote (a) to Table 2a.(c) Total Restructuring, acquisition-related and other costs cash payments of $62,634 are broken down as follows:Project TypeAmount PaidMedicis

    32,810Intellectual property migration

    6,536Other

    4,522Europe (including Nature Produkt & Lek-Am)

    4,435Manufacturing integration (various deals)

    3,640U.S. restructuring

    2,767OraPharma

    2,490Ophthalmology (QLT and Eyetech)

    1,992Swiss Herbal/Afexa

    1,948Systems integration (various deals U.S./Canada)

    1,494Total$
    2,634Expense TypeAmount PaidSeverance payments

    29,265Integration related consulting, duplicative labor, transition services, and other

    26,212Facility closure costs, other manufacturing integration, and other

    3,604Acquisition-related costs paid to 3rd parties

    3,553Total$
    2,634 Valeant Pharmaceuticals International, Inc.Table 6Organic Growth - by Segment For the Three Months Ended March 31, 2013(In thousands) For the Three Months Ended March 31, 2013  Organic growth (a)

    (b) (b)  (b)  (1) QTD
    2013 (2) Acq impact (3) QTD
    Same store (4) QTD
    2012 (5) Pro Forma Adj (6) Pro Forma 2012 (7) Currency impact Same store (8) Currency impact Acq (9) Divestitures / Discontinuations (c)Pro Forma (1)+(7)+(8)+(9) / (6)Same store (3)+(7) / (4)-(9)U.S. Promoted

    478.6

    217.9

    260.7250.6

    233.9

    484.5-

    -4.80%6%U.S. Neurology & Other (d)158.4

    24.0

    134.4153.5

    15.7

    169.1-

    -3.5-4%-10%Canada/Australia
     (e) 119.0

    14.7

    104.3121.5

    16.9

    138.41.1

    0.13.0-11%-11%Developed Markets755.9256.6499.4525.6266.4792.01.10.111.3-3%-3%Emerging Markets - Central/Eastern Europe

    178.6

    36.0

    142.6134.3

    32.1

    166.4(0.3)

    0.25.911%11%Emerging Markets - Latin America

    81.7

    12.0

    69.870.9

    11.6

    82.52.6

    0.53.27%7%Emerging Markets - Southeast Asia/Africa

    26.4

    -

    26.421.9

    -

    21.91.7

    -0.028%28%Emerging Markets286.848.0238.8227.143.7270.94.10.79.211%11%Total product sales1,042.7304.5738.2752.7310.21,062.95.20.820.51%2%Normalized for:
    ) Generic impact of Cesamet, BenzaClin and other generics2) Assets held for sale (various brands in Australia and Canada) For the Three Months Ended March 31, 2013  Organic growth (a)

    (b) (b)  (b)  (1) QTD
    2013 (2) Acq impact (3) QTD
    Same store (4) QTD
    2012 (5) Pro Forma Adj (6) Pro Forma 2012 (7) Currency impact Same store (8) Currency impact Acq (9) Divestitures / Discontinuations (c) Pro Forma (1)+(7)+(8)+(9) / (6)Same store (3)+(7) / (4)-(9)U.S. Promoted (f) (h)473.9

    217.9

    256.0233.8

    233.9

    467.7-

    -4.82%12%U.S. Neurology & Other (d) (i)158.4

    24.0

    134.4153.5

    15.7

    169.1-

    -3.5-4%-10%Canada/Australia
     (e) (g)106.4

    14.7

    91.791.6

    16.9

    108.51.1

    0.13.02%5%Developed Markets738.7256.6482.1478.9266.4745.31.10.111.31%3%Emerging Markets - Central/Eastern Europe

    178.6

    36.0

    142.6134.3

    32.1

    166.4(0.3)

    0.25.911%11%Emerging Markets - Latin America

    81.7

    12.0

    69.870.9

    11.6

    82.52.6

    0.53.27%7%Emerging Markets - Southeast Asia/Africa

    26.4

    -

    26.421.9

    -

    21.91.7

    -0.028%28%Emerging Markets286.848.0238.8227.143.7270.94.10.79.211%11%Total product sales (j)1,025.5304.5720.9706.0310.21,016.25.20.820.54%6%(a) Note: Currency effect for constant currency sales is determined by comparing 2013 reported amounts adjusted to exclude currency impact, calculated using 2012 monthly average exchange rates, to the actual 2012 reported amounts. Constant currency sales is not a GAAP-defined measure of revenue growth. Constant currency sales as defined and presented by us may not be comparable to similar measures reported by other companies. (b) See footnote (a) to Table 2a.(c) Includes divestitures, discontinuations and supply interruptions.(d) Includes Valeant's attributable portion of revenue from joint ventures (JV) -  $1.7M Q1'13.(e) Includes Valeant's attributable portion of revenue from joint ventures (JV) -  $1.8M Q1'12 and $2.2M Q1'13.(f)  Excludes revenue from genericized products of $16.8M Q1'12 and $4.7M Q1'13.(g) Excludes revenue from genericized products and assets held for sale of $29.9M Q1'12 and $12.6M Q1'13.(h) Includes impact of $22.5M in wholesaler inventory reductions on Medicis brands.  Excluding this impact, pro forma organic growth is 7% for the quarter.(i)  Includes impact of $1.5M in wholesaler inventory reductions on Medicis brands.  Excluding this impact, pro forma organic growth is 3% for the quarter.(j)  Includes impact of $24.0M in wholesaler inventory reductions on Medicis brands.  Excluding this impact, pro forma organic growth is 6% for the quarter. 

    (Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


    '/>"/>
    SOURCE Valeant Pharmaceuticals International, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel
    2. Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.
    3. American Skin Association Announces New Member Of The Board J. Michael Pearson And New Education Council Member Ryan Weldon Of Valeant Pharmaceuticals International, Inc.
    4. Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc.
    5. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
    6. Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013
    7. Valeant Pharmaceuticals Provides Update to Recent Event
    8. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
    9. Valeant Pharmaceuticals Announces Private Exchange Offer
    10. Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
    11. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
    (Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
    (Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
    Breaking Medicine Technology:
    (Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
    (Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
    (Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
    (Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
    (Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
    Breaking Medicine News(10 mins):